These results provide new insights into the occurrence and progression of ESCC and indicate that the S1P/S1PR1/SAA1/β-catenin axis may serve as a potential therapeutic target in ESCC. This evidence concerns the gene SAA1 and esophageal squamous cell carcinoma.